IL1A and cancer: In summary, while blockade of IL‐1α seems to be effective in reducing inflammation-associated symptoms such as cachexia or other cancer-related symptoms (pain, fatigue, anorexia) in patients with advanced malignant disease, a benefit in overall survival has so far not been shown.